溶质载体超家族50蛋白在乳腺癌中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2022.05.007

癌变·畸变·突变 ›› 2022, Vol. 34 ›› Issue (5): 373-377.doi: 10.3969/j.issn.1004-616x.2022.05.007

• 论著 • 上一篇

溶质载体超家族50蛋白在乳腺癌中的表达及其临床意义

张海智¹, 温晓芬², 黄彬亮², 林慧², 薛文武², 曾德², 林丹霞²

1. 高州市人民医院肿瘤内科一区, 广东茂名 525000;
2. 汕头大学医学院附属肿瘤医院肿瘤内科, 广东汕头 515041

收稿日期:2022-05-09 修回日期:2022-08-31 发布日期:2022-10-09
通讯作者: 林丹霞
作者简介:张海智,E-mail:15917905760@163.com;温晓芬,E-mail:xiaofenwen53@126.com。
基金资助:
汕头市科技计划医疗卫生项目(1908221652638)

Expression and clinical significance of SLC50A1 in breast carcinomas

ZHANG Haizhi¹, WEN Xiaofen², HUANG Binliang², LIN Hui², XUE Wenwu², ZENG De², LIN Danxia²

1. Medical Oncology Division 1, Gaozhou People' Hospital, Maoming 525000;
2. Department of Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China

Received:2022-05-09 Revised:2022-08-31 Published:2022-10-09

摘要/Abstract

摘要： 目的：探讨溶质载体家族50蛋白成员1(SLC50A1)在乳腺癌中的表达及其临床意义。方法：选取符合入组标准的乳腺癌患者 39例，使用酶联免疫吸附测定法(ELISA)对入组患者的血浆进行 SLC50A1蛋白浓度检测。分别使用 Kendall's tau-b以及Mann-Whitney U检验对SLC50A1蛋白浓度与患者治疗期间的临床指标进行相关性及差异性分析，并根据log-rank检验结果进行多因素 Cox回归分析。应用生物信息学技术分析 TCGA数据库中乳腺癌组织及癌旁正常组织 SLC50A1基因表达水平的差异。结果：乳腺癌患者血浆SLC50A1水平在早期与晚期患者组、雌激素受体阳性和阴性组、Ki67高表达与低表达组中的差异均有统计学意义(P<0.05)，SLC50A1表达与 CA153水平存在正相关关系(Kendall's tau-b=0.257，P=0.004)。Cox回归分析结果显示 SLC50A1表达水平是乳腺癌患者的独立预后因素(HR=0.385，P=0.03)。TCGA数据库分析结果表明，乳腺癌组织中的SLC50A1基因表达水平较癌旁正常组织升高(P<0.01)。结论：晚期乳腺癌患者血浆 SLC50A1水平升高，SLC50A1表达水平是乳腺癌的独立预后因素，SLC50A1有望作为乳腺癌预后预测与治疗的靶点。

关键词: 乳腺癌, SLC50A1, 预后, 生物标志物

Abstract: OBJECTIVE: To investigate expression of SLC50A1 and its significance in breast cancers (BC).METHODS: Plasma samples from 39 BC patients who met the inclusion criteria of this study were investigated using the enzyme-linked immunosorbent assay.The Mann-Whitney U-test and Kendall's Tau-b were used to analyze differences and correlations between SLC50A1 protein levels and their clinical data.The multivariate Cox regression was used to investigate prognostic significance of SLC50A1 according to the results of the log-rank test.Furthermore,the TCGA database was downloaded to compared different expressions of SLC50A1 from 1 109 BC and 113 adjacent normal tissues.RESULTS: Clinical data from the BC patients indicated that SLC50A1 protein expression was associated with metastasis,hormone receptor and Ki67(P< 0.05).Correlation analyses of plasma SLC50A1 levels indicated a positive correlation between plasma SLC50A1 level and CA153,Kendall's Tau-b=0.257(P=0.004).Multivariate Cox regression analyses indicated that SLC50A1 was an independent prognostic factor in BC patients (HR=0.385,P=0.03).The TCGA data analyses indicated that the SLC50A1 expression levels were higher in BC than in adjacent tissues (P<0.01).CONCLUSION: Plasma SLC50A1 levels were increased in advanced BC,and SLC50A1 expression was an independent prognostic factor for BC.SLC50A1 may be useful as a target for prognosis prediction and therapy of BC.

Key words: breast cancer, SLC50A1, prognosis, biomarker

中图分类号:

R737.9

张海智, 温晓芬, 黄彬亮, 林慧, 薛文武, 曾德, 林丹霞. 溶质载体超家族50蛋白在乳腺癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(5): 373-377.

ZHANG Haizhi, WEN Xiaofen, HUANG Binliang, LIN Hui, XUE Wenwu, ZENG De, LIN Danxia. Expression and clinical significance of SLC50A1 in breast carcinomas[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 373-377.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7):783-791.
[3] 张雪,董晓平,管雅喆,等.女性乳腺癌流行病学趋势及危险因素研究进展[J].肿瘤防治研究, 2021, 48(1):87-92.
[4] TARIGHATI E, KEIVAN H, MAHANI H. A review of prognostic and predictive biomarkers in breast cancer[J]. Clin Exp Med, 2022:1-16.
[5] LI G, HU J, HU G H. Biomarker studies in early detection and prognosis of breast cancer[J]. Adv Exp Med Biol, 2017, 1026:27-39.
[6] ŚWITNICKI M P, JUUL M, MADSEN T, et al. PINCAGE:probabilistic integration of cancer genomics data for perturbed gene identification and sample classification[J]. Bioinformatics, 2016, 32(9):1353-1365.
[7] WANG Y, SHU Y, GU C Y, et al. The novel sugar transporter SLC50A1 as a potential serum-based diagnostic and prognostic biomarker for breast cancer[J]. Cancer Manag Res, 2019, 11:865-876.
[8] BUDNY A, STAROSŁAWSKA E, BUDNY B, et al. Epidemiology and diagnosis of breast cancer[J]. Pol Merkur Lekarski, 2019, 46(275):195-204.
[9] LI J X, LIU L Y, FENG Z W, et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype:a cohort study[J]. Breast Cancer, 2020, 27(4):621-630.
[10] ZHANG F, DE HAAN-DU J, SIDORENKOV G, et al. Type 2 diabetes mellitus and clinicopathological tumor characteristics in women diagnosed with breast cancer:a systematic review and Meta-analysis[J]. Cancers, 2021, 13(19):4992.
[11] AGRAWAL S, WOZNIAK M, LUC M, et al. Insulin and novel thioglycosides exert suppressive effect on human breast and colon carcinoma cells[J]. Oncotarget, 2017, 8(69):114173-114182.
[12] CHEN L Q, HOU B H, LALONDE S, et al. Sugar transporters for intercellular exchange and nutrition of pathogens[J]. Nature, 2010, 468(7323):527-532.
[13] TAGOH H, KISHI H, MURAGUCHI A. Molecular cloning and characterization of a novel stromal cell-derived cDNA encoding a protein that facilitates gene activation of recombination activating gene (RAG)-1 in human lymphoid progenitors[J]. Biochem Biophys Res Commun, 1996, 221(3):744-749.
[14] VILLAGRÁN M, MUÑOZ M, INOSTROZA E, et al. GLUT1 and GLUT8 support lactose synthesis in Golgi of murine mammary epithelial cells[J]. J Physiol Biochem, 2019, 75(2):209-215.
[15] LIMA-OLIVEIRA G, MONNERET D, GUERBER F, et al. Sample management for clinical biochemistry assays:are serum and plasma interchangeable specimens?[J]. Crit Rev Clin Lab Sci, 2018, 55(7):480-500.
[16] JAROS J A J, GUEST P C, BAHN S, et al. Affinity depletion of plasma and serum for mass spectrometry-based proteome analysis[J]. Methods Mol Biol Clifton N J, 2013, 1002:1-11.
[17] WANG R P, HAN Y, ZHAO Z X, et al. Link synthetic lethality to drug sensitivity of cancer cells[J]. Brief Bioinform, 2017, 20(4):1295-1307.
[18] ZHANG D S, LI J, WANG F Z, et al. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy[J]. Cancer Lett, 2014, 355(2):176-183.
[19] FAN T J, SUN G H, SUN X D, et al. Tumor energy metabolism and potential of 3-bromopyruvate as an inhibitor of aerobic glycolysis:implications in tumor treatment[J]. Cancers, 2019, 11(3):317.

溶质载体超家族50蛋白在乳腺癌中的表达及其临床意义

Expression and clinical significance of SLC50A1 in breast carcinomas

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	毕佳欣, 王晓雪, 赵若晗, 韩旭, 宋洁. 着丝粒蛋白T在乳腺癌中表达及其启动子区变异的研究[J]. 癌变·畸变·突变, 2022, 34(5): 327-334.
[2]	于运亮, 王莉莉, 李婷, 封建凯. 嘌呤能受体X1与肺腺癌预后及免疫细胞浸润的相关性研究[J]. 癌变·畸变·突变, 2022, 34(5): 353-360,365.
[3]	王婷, 张雯雯, 张永欣, 曾勇, 王俊玲, 李成云. miR-101基因簇与食管癌发病风险的病例对照研究[J]. 癌变·畸变·突变, 2022, 34(4): 273-278.
[4]	张玉铃, 刘迪填, 陈春发. CD68巨噬细胞浸润对原发性食管小细胞癌预后的影响[J]. 癌变·畸变·突变, 2022, 34(4): 279-283.
[5]	王绪娟, 罗永鑫, 李陈强, 王汝晋, 郑婷婷. 术前检查指标dNLR、SII、CRP/ALB对乳腺癌复发转移的预测价值[J]. 癌变·畸变·突变, 2022, 34(4): 284-288,323.
[6]	张月, 王耀一, 武雪亮, 张志生, 杨修明, 姜洋, 乔志飞, 梁晚平, 薛军. ¹²⁵I粒子联合AZD1152对三阴性乳腺癌细胞增殖和凋亡的影响[J]. 癌变·畸变·突变, 2022, 34(4): 295-299,306.
[7]	范晓杰, 李清靖, 谷丽娜, 桑梅香, 单保恩. 黑色素瘤相关抗原A基因在乳腺癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(3): 184-191.
[8]	辛雨濛, 梁桓熙, 孙震晓. 甘草干姜汤抗小鼠乳腺癌实验研究[J]. 癌变·畸变·突变, 2022, 34(2): 88-92.
[9]	梁峰, 张玮, 李飞, 王胜杰, 杜宇晶, 张迎春. 长链非编码RNACASC9在结直肠癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(2): 110-113.
[10]	郭晓娟, 王金西, 牛广旭, 田云霄. EGFR与HER-2在不同分子类型乳腺癌中的表达及其相关性分析[J]. 癌变·畸变·突变, 2022, 34(2): 119-123,148.
[11]	辛雨濛, 梁桓熙, 余悦华, 孙震晓. 基于网络药理学和分子对接法预测甘草干姜汤抗乳腺癌的主要活性成分及作用机制[J]. 癌变·畸变·突变, 2022, 34(1): 7-13.
[12]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[13]	赵岩, 孙震晓. 二甲双胍抑制人MDA-MB-231细胞增殖及迁移的体外实验研究[J]. 癌变·畸变·突变, 2022, 34(1): 35-39.
[14]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[15]	方煜彤, 张群琛, 洪超群, 陈春发, 陈炯玉, 张任栋, 吴俊东. 乳腺癌中miR-221、miR-222表达水平对GATA3和FOXA1蛋白的影响及其作用机制[J]. 癌变·畸变·突变, 2021, 33(6): 435-441,460.